BIIB
Price
$143.63
Change
+$2.28 (+1.61%)
Updated
Sep 9, 04:59 PM (EDT)
Capitalization
21.05B
42 days until earnings call
JNJ
Price
$176.97
Change
-$1.16 (-0.65%)
Updated
Sep 9, 04:59 PM (EDT)
Capitalization
426.18B
34 days until earnings call
Interact to see
Advertisement

BIIB vs JNJ

Header iconBIIB vs JNJ Comparison
Open Charts BIIB vs JNJBanner chart's image
Biogen
Price$143.63
Change+$2.28 (+1.61%)
Volume$81.02K
Capitalization21.05B
Johnson & Johnson
Price$176.97
Change-$1.16 (-0.65%)
Volume$61.73K
Capitalization426.18B
BIIB vs JNJ Comparison Chart in %
Loading...
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BIIB vs. JNJ commentary
Sep 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Buy and JNJ is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 10, 2025
Stock price -- (BIIB: $143.60 vs. JNJ: $176.96)
Brand notoriety: BIIB and JNJ are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BIIB: 101% vs. JNJ: 71%
Market capitalization -- BIIB: $21.05B vs. JNJ: $426.18B
BIIB [@Pharmaceuticals: Major] is valued at $21.05B. JNJ’s [@Pharmaceuticals: Major] market capitalization is $426.18B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $672.89B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BIIB’s FA Score shows that 0 FA rating(s) are green whileJNJ’s FA Score has 4 green FA rating(s).

  • BIIB’s FA Score: 0 green, 5 red.
  • JNJ’s FA Score: 4 green, 1 red.
According to our system of comparison, JNJ is a better buy in the long-term than BIIB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BIIB’s TA Score shows that 7 TA indicator(s) are bullish while JNJ’s TA Score has 2 bullish TA indicator(s).

  • BIIB’s TA Score: 7 bullish, 2 bearish.
  • JNJ’s TA Score: 2 bullish, 4 bearish.
According to our system of comparison, BIIB is a better buy in the short-term than JNJ.

Price Growth

BIIB (@Pharmaceuticals: Major) experienced а +2.84% price change this week, while JNJ (@Pharmaceuticals: Major) price change was -0.62% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.10%. For the same industry, the average monthly price growth was +4.65%, and the average quarterly price growth was +13.54%.

Reported Earning Dates

BIIB is expected to report earnings on Oct 22, 2025.

JNJ is expected to report earnings on Oct 14, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.10% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JNJ($426B) has a higher market cap than BIIB($21.1B). JNJ has higher P/E ratio than BIIB: JNJ (18.95) vs BIIB (13.74). JNJ YTD gains are higher at: 25.312 vs. BIIB (-6.095). JNJ has higher annual earnings (EBITDA): 35.6B vs. BIIB (2.79B). JNJ has more cash in the bank: 18.9B vs. BIIB (2.76B). BIIB has less debt than JNJ: BIIB (6.6B) vs JNJ (50.8B). JNJ has higher revenues than BIIB: JNJ (90.6B) vs BIIB (10B).
BIIBJNJBIIB / JNJ
Capitalization21.1B426B5%
EBITDA2.79B35.6B8%
Gain YTD-6.09525.312-24%
P/E Ratio13.7418.9573%
Revenue10B90.6B11%
Total Cash2.76B18.9B15%
Total Debt6.6B50.8B13%
FUNDAMENTALS RATINGS
BIIB vs JNJ: Fundamental Ratings
BIIB
JNJ
OUTLOOK RATING
1..100
1277
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
10027
SMR RATING
1..100
7432
PRICE GROWTH RATING
1..100
5731
P/E GROWTH RATING
1..100
9381
SEASONALITY SCORE
1..100
5065

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JNJ's Valuation (16) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (91) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than BIIB’s over the last 12 months.

JNJ's Profit vs Risk Rating (27) in the Pharmaceuticals Major industry is significantly better than the same rating for BIIB (100) in the Biotechnology industry. This means that JNJ’s stock grew significantly faster than BIIB’s over the last 12 months.

JNJ's SMR Rating (32) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (74) in the Biotechnology industry. This means that JNJ’s stock grew somewhat faster than BIIB’s over the last 12 months.

JNJ's Price Growth Rating (31) in the Pharmaceuticals Major industry is in the same range as BIIB (57) in the Biotechnology industry. This means that JNJ’s stock grew similarly to BIIB’s over the last 12 months.

JNJ's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as BIIB (93) in the Biotechnology industry. This means that JNJ’s stock grew similarly to BIIB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BIIBJNJ
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
22%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
43%
Momentum
ODDS (%)
Bullish Trend 2 days ago
58%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
54%
Bearish Trend 2 days ago
33%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
42%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
42%
Advances
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 8 days ago
42%
Declines
ODDS (%)
Bearish Trend 12 days ago
69%
Bearish Trend 2 days ago
43%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
78%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
57%
Bullish Trend 2 days ago
43%
View a ticker or compare two or three
Interact to see
Advertisement
BIIB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
JNJ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
IUSG159.950.64
+0.40%
iShares Core S&P US Growth ETF
NMB25.050.03
+0.12%
Simplify National Muni Bond ETF
DLY15.65N/A
N/A
DoubleLine Yield Opportunities Fund
MOTI37.30-0.01
-0.02%
VanEck Morningstar Intl Moat ETF
AVMA64.34-0.06
-0.10%
Avantis Moderate Allocation ETF

JNJ and

Correlation & Price change

A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JNJ
1D Price
Change %
JNJ100%
-0.66%
PFE - JNJ
59%
Loosely correlated
+0.65%
NVS - JNJ
54%
Loosely correlated
-0.51%
GSK - JNJ
48%
Loosely correlated
+1.82%
BIIB - JNJ
44%
Loosely correlated
+1.59%
SNY - JNJ
43%
Loosely correlated
+1.39%
More